CNS(Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNSPreparing protocol resubmission to incorporate FDA guidance on Phase III PORTICO-2 trial in aggression in BPDOngo ...
Calumet, Inc. (NASDAQ: CLMT) (the "Company," "Calumet," "we," "our" or "us") today reported its results for the fourth quarter and year ended December 31, 2025, as follows: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results